McGrail K, Granado-Martínez P, Orsenigo R, Caratù G, Nieto P, Heyn H, Ferrer B, Hernández-Losa J, Muñoz-Couselo E, García-Patos V, Recio JA
Transcriptional reprogramming triggered by neonatal UV radiation or Lkb1 loss prevents BRAFV600E-induced growth arrest in melanocytes.
Oncogene. 2025 Jun;44(21):1592-1608.
DOI: 10.1038/s41388-025-03339-7
IF: 7.4
RESEARCH GROUPS
Biomedical Research in Melanoma
16
Number of publications
87.50
%
% Q1
37.50
%
% D1
37.50
%
% Leadership
50.00
%
% Female Leadership
1.54
CROWN (2021-2025)
22.58
%
HCP10% (2021-2025)
87.50
%
% Open access
31.25
%
% International Collaboration
1
Highly cited papers / HCP 1% (2021-2025)
1
Publications in high-IF journals with high Altmetric scores
6
Number of Ongoing Projectes (total)
0
International ongoing projects
1
Number of New projects (total)
0
International new projects
6
Number of Active clinical Trials
1
Number of New Clinical Trials
0
Number of Theses
This year, we advanced understanding of melanoma tumor biology by demonstrating that UVB cooperates with BRAFV600E and LKB1 loss to impair DNA damage repair and drive a neural-like melanoma phenotype. We also showed that neonatal UVB exposure induces transcriptional reprogramming that bypasses BRAFV600E-driven growth arrest, enabling melanoma initiation independently of nevus progression. Several UV-regulated genes were linked to poor survival, enhanced transformation, and multidrug resistance, emerging as potential therapeutic targets, including UPP1. Clinically, we found that the mutational landscape of SPTCL is broader than previously recognized, identifying TP53 P72R and DNMT3A T735C as relevant contributors, while LEP lacks these alterations, supporting distinct pathogenic mechanisms. We also documented severe vitiligo-like depigmentation following imiquimod treatment for superficial BCC, with recurrence despite intense inflammation.
CORE/MISSIONS
- Aging
- AI, Data, Imaging & Digital Health
- Environmental & Public Health
- Innovative & Advanced Therapies
- Transplant & Immunomodulation
PROGRAMS
TEAM
Group Leader
Juan A. Recio Conde, Vicenç Garcia Patos
Principal Investigator (PI)
Juan A. Recio Conde
Researchers
Kimberley McGrail, Paula Granado Martínez, Vicenç Garcia Patos, Berta Ferrer
PhD Students
Roberto Orsenigo, Yuxin Ding
SELECTED PUBLICATIONS
McGrail K, González-Sánchez E, Granado-Martínez P, Orsenigo R, Ding Y, Ferrer B, Hernández-Losa J, Ortega I, Martín-Caballero J, Muñoz-Couselo E, García-Patos V, Recio JA
Loss of Lkb1 cooperates with BrafV600E and ultraviolet radiation, increasing melanoma multiplicity and neural-like dedifferentiation.
Mol Oncol. 2025 Feb;19(2):329-343.
DOI: 10.1002/1878-0261.13715
IF: 5.7
Machan S, Rodríguez M, Manso R, Borregón J, Chamizo C, Alonso-Alonso R, Rodríguez-Peralto JL, Torres Nieto MÁ, Monteagudo C, García Toro E, Cerroni L, García C, Estrach T, García Herrera A, Ferrer B, García-Patos V, Segues N, Díaz de la Pinta FJ, Afonso-Martin JL, Peñate Y, Limeres-Gonzalez MÁ, González-Núñez MÁ, González-Cruz C, García Fernández E, Cereceda L, Minguez P, de la Fuente L, Requena L, Rodríguez-Pinilla SM
Different Mutational Profiles of Subcutaneous Panniculitis-like T-cell Lymphoma and Lupus Panniculitis: An Additional Case Series.
Actas Dermosifiliogr. 2025 Mar;116(3):210-217.
DOI: 10.1016/j.ad.2024.06.006
IF: 2.8
Gómez-Tomás Á, Falguera-Mayoral M, García-Patos V, Bassas-Freixas P, Palao-Doménech R, Ferrer-Fábrega B, Bodet D.
Vitiligo-like basal cell carcinoma: An emerging entity in young women.
Indian J Dermatol Venereol Leprol. 2025 Jul-Aug;91(4):505-507.
DOI: 10.25259/IJDVL_672_2023
IF: 3.4
SELECTED PROJECTS
p38α tumor-dependent immune evasive mechanisms in melanoma.
Principal Investigator: Juan A. Recio
Agency: Instituto de Salud Carlos III
Funding: 321.250 €
Period: 01/01/2024-31/12/2026
Development of TET2 activating drugs for the treatment of melanoma.
Principal Investigator: Juan Angel Recio Conde, Isabel Puig, ONIRIA (VHIR, VHIO)
Agency: Ministerio Ciencia e Innovación
Funding: 723.392,47 €
Period: 15/11/2023-31/10/2026
PATENTS
DISSEMINATION ACTIVITIES
III ENCUENTRO INVESTIGADORES CONTRA EL CÁNCER
Place: Madrid
Date: 12/3/25
Brief: Kimberly McGRail shared her work on immunooncology
